The EURTAC trial demonstrated efficacy of erlotinib over chemotherapy for first-line treatment of European advanced EGFR-mutant non-small-cell lung cancer (NSCLC) patients1. This evidence concerns the gene EGFR and non-small cell lung carcinoma.